The interest in treatment for heart failure is shifting away from traditional inotropic therapy towards drugs that modulate neuroendocrine activity. Data are presented on the assessment of endothelin receptor blockers, as well as angiotensin II type 1 receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure. Ongoing studies assessing beta-blockers and new calcium channel blockers in heart failure are described.
|Original language||English (US)|
|Journal||Canadian Journal of Cardiology|
|Issue number||SUPPL. D|
|State||Published - Dec 1 1998|
- Clinical trials
- Heart failure